SESN Stock Overview
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.71|
|52 Week High||US$6.04|
|52 Week Low||US$0.70|
|1 Month Change||-20.14%|
|3 Month Change||-38.60%|
|1 Year Change||-57.21%|
|3 Year Change||-6.35%|
|5 Year Change||-67.61%|
|Change since IPO||-93.49%|
Recent News & Updates
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Sesen Bio: Interesting Price Drop After CRL
Sesen received a CRL in August. Another trial will be needed. Sesen held a Type A meeting with the FDA on Oct. 29 on the CMC questions.
Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
The US FDA published the warning letter on October 27, 2021, just 2 days before CMC Type A meeting with Sesen Bio. The move informed its rejection of the BLA. Ahead of the Type A meeting, the burden of proof will be on Sesen’s side to show the efficacy of Vicineum post-2017. Sesen Bio is gearing towards product commercialization with strategic hires into 2022. Study shows that high-prescribing urologists would use a treatment agent branded with Vicineum in more than 80% of the BCG-unresponsive NMIBC patients as opposed to 17% with Keytruda. Sesen Bio is able to fund its capital operations including R&D until 2023 when it is expected to begin commercialization of Vicineum.
|SESN||US Biotechs||US Market|
Return vs Industry: SESN underperformed the US Biotechs industry which returned -22% over the past year.
Return vs Market: SESN underperformed the US Market which returned 4.2% over the past year.
|SESN Average Weekly Movement||10.3%|
|Biotechs Industry Average Movement||10.2%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: SESN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: SESN's weekly volatility has decreased from 17% to 10% over the past year.
About the Company
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company’s lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca’s checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck.
Sesen Bio Fundamentals Summary
|SESN fundamental statistics|
Is SESN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SESN income statement (TTM)|
|Cost of Revenue||US$23.84m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.12|
|Net Profit Margin||-371.16%|
How did SESN perform over the long term?See historical performance and comparison
Is Sesen Bio undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SESN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SESN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SESN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: SESN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SESN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SESN is good value based on its PB Ratio (0.9x) compared to the US Biotechs industry average (1.9x).
How is Sesen Bio forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SESN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SESN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SESN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SESN's revenue (46.5% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: SESN's revenue (46.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SESN's Return on Equity is forecast to be high in 3 years time
How has Sesen Bio performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SESN is currently unprofitable.
Growing Profit Margin: SESN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SESN is unprofitable, and losses have increased over the past 5 years at a rate of 36% per year.
Accelerating Growth: Unable to compare SESN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SESN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: SESN has a negative Return on Equity (-15.09%), as it is currently unprofitable.
How is Sesen Bio's financial position?
Financial Position Analysis
Short Term Liabilities: SESN's short term assets ($200.5M) exceed its short term liabilities ($12.6M).
Long Term Liabilities: SESN's short term assets ($200.5M) exceed its long term liabilities ($62.1M).
Debt to Equity History and Analysis
Debt Level: SESN is debt free.
Reducing Debt: SESN had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SESN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SESN has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 20.3% each year.
What is Sesen Bio current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SESN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SESN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SESN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SESN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SESN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thomas Cannell (59 yo)
Dr. Thomas R. Cannell, DVM, has been President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD1.70M) is above average for companies of similar size in the US market ($USD584.85K).
Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.
Experienced Management: SESN's management team is considered experienced (2.4 years average tenure).
Experienced Board: SESN's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.2%.
Sesen Bio, Inc.'s employee growth, exchange listings and data sources
- Name: Sesen Bio, Inc.
- Ticker: SESN
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$140.841m
- Shares outstanding: 199.46m
- Website: https://www.sesenbio.com
Number of Employees
- Sesen Bio, Inc.
- 245 First Street
- Suite 1800
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/22 23:30|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.